<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01279577</url>
  </required_header>
  <id_info>
    <org_study_id>TSU-2/CDA</org_study_id>
    <secondary_id>2006-000720-13</secondary_id>
    <nct_id>NCT01279577</nct_id>
  </id_info>
  <brief_title>Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease</brief_title>
  <acronym>TRUST-2</acronym>
  <official_title>Double-blind, Randomised, Placebo-controlled, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Three Different Dosages of Oral Trichuris Suis Ova (TSO) Suspension in Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will run in centers in Germany, Denmark, Austria, Czech Republic, and Switzerland,
      only.

      This proof-of-concept study aims to evaluate the efficacy of three doses of oral TSO
      suspension vs. placebo for the induction of remission in Crohn's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinical remission at week 12 (LOCF) defined as a CDAI&lt; 150</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of &gt; 100 points in CDAI</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">254</enrollment>
  <condition>Crohn´s Disease</condition>
  <arm_group>
    <arm_group_label>Low dose TSO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose suspension of TSO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose TSO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose suspension of TSO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose TSO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose suspension of TSO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose TSO</intervention_name>
    <description>Low dose TSO suspension</description>
    <arm_group_label>Low dose TSO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medium dose TSO</intervention_name>
    <description>Medium dose TSO suspension</description>
    <arm_group_label>Medium dose TSO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose TSO</intervention_name>
    <description>High dose TSO suspension</description>
    <arm_group_label>High dose TSO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Signed informed consent,

          -  Man or woman between 18 and 75 years of age,

          -  Established diagnosis of Crohn's disease (CD) since at least 3 months prior to
             screening confirmed by endoscopic and histological, or endoscopic and radiological
             criteria,

          -  Negative pregnancy test in females of childbearing potential.

        Major Exclusion Criteria:

          -  Bowel surgery within the last 3 months prior to baseline,

          -  Resection of more than 50 cm of the ileum,

          -  Ileostomy or colostomy,

          -  Septic complications,

          -  Evidence of infectious diarrhoea (i.e., pathogenic bacteria or Clostridium difficile
             toxin in stool culture),

          -  Abscess, perforation, fistulas, or perianal lesions,

          -  Immediate surgery required (e.g., major stenosis, serious bleeding, peritonitis,
             ileus),

          -  Clinical signs of stricturing disease,

          -  Parenteral or tube feeding,

          -  Abnormal hepatic function (ALT or ALP &gt; 2.5 x upper limit of normal [ULN] at
             screening), liver cirrhosis, or portal hypertension,

          -  Abnormal renal function (Cystatin C &gt; ULN) at screening,

          -  Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder,
             which in the opinion of the investigator might have an influence on the patient's
             compliance or the interpretation of the results,

          -  Any condition associated with significant immunosuppression,

          -  Active malignancy or treatment with anticancer drugs during the last 5 years.

          -  Existing or intended pregnancy or breast-feeding,

          -  Participation in another clinical trial within the last 30 days, simultaneous
             participation in another clinical trial, or previous participation in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen Schölmerich, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Johann Wolfgang Goethe-Universität</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität</name>
      <address>
        <city>Frankfurt a.M.</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn´s disease</keyword>
  <keyword>Trichuris suis</keyword>
  <keyword>randomized</keyword>
  <keyword>placebo</keyword>
  <keyword>induction of remission</keyword>
  <keyword>porcine whipworm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

